Banque Cantonale Vaudoise Has $4.36 Million Position in Boston Scientific Corporation $BSX

Banque Cantonale Vaudoise cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 14.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 44,609 shares of the medical equipment provider’s stock after selling 7,232 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Boston Scientific were worth $4,356,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BSX. Norges Bank acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $2,089,937,000. Edgewood Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $746,655,000. Parnassus Investments LLC grew its stake in shares of Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after purchasing an additional 6,868,459 shares during the period. Egerton Capital UK LLP increased its holdings in Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in Boston Scientific by 133.5% in the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Company actions that may support the share price: Boston Scientific negotiated a new $3.0 billion revolving credit facility (matures 2031), expanded its share‑repurchase authorization to $5.0 billion, and added two senior healthcare/finance leaders to the board — moves that can bolster liquidity and signal confidence in capital returns. Is Boston Scientific (BSX) Balancing Buybacks and Litigation or Masking Deeper Electrophysiology Risks?
• Neutral Sentiment: Options activity: traders bought ~23,040 put contracts on Monday — roughly a 27% increase vs. typical daily put volume — indicating elevated hedging or bearish interest but not a definitive directional signal by itself.
• Negative Sentiment: Legal and regulatory risk escalating: multiple law firms (Rosen, Levi & Korsinsky, Robbins, Bronstein, Schall, Faruqi & Faruqi) have filed or announced investigations and class actions on behalf of BSX investors covering the July 23, 2025–Feb 3, 2026 period; lead‑plaintiff deadlines have been set (May 4, 2026 in several notices). The suits and media coverage cite a Class I recall of the AXIOS Stent & Delivery System, a federal probe of disclosures/product safety, and allegations of misleading statements about the U.S. electrophysiology business — risks that could lead to settlements, fines, or reputational damage and weigh on earnings and cash flow. Shareholders of Boston Scientific Corporation Should Contact Levi & Korsinsky Boston Scientific Recall And Lawsuits Test Earnings Power And Capital Plans

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.7%

NYSE BSX opened at $71.88 on Tuesday. Boston Scientific Corporation has a 52 week low of $69.52 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock’s 50 day moving average price is $84.55 and its two-hundred day moving average price is $94.24. The stock has a market capitalization of $106.66 billion, a price-to-earnings ratio of 37.05, a PEG ratio of 1.00 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the business earned $0.70 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent analyst reports. Evercore reduced their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Morgan Stanley lowered their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Canaccord Genuity Group cut their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Barclays decreased their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a report on Tuesday, February 3rd. Finally, Stifel Nicolaus lowered their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.